You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 18, 2024

~ Buy the EUCRISA (crisaborole) Drug Profile, 2024 PDF Report in the Report Store ~

EUCRISA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Eucrisa, and what generic alternatives are available?

Eucrisa is a drug marketed by Anacor Pharms Inc and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-seven patent family members in twenty-eight countries.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the crisaborole profile page.

DrugPatentWatch® Generic Entry Outlook for Eucrisa

Eucrisa was eligible for patent challenges on December 14, 2020.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 29, 2029. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Drug patent expirations by year for EUCRISA
Drug Prices for EUCRISA

See drug prices for EUCRISA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for EUCRISA
Generic Entry Date for EUCRISA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
OINTMENT;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for EUCRISA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Colorado, DenverPhase 2
Boston UniversityPhase 4
Applied Biology, Inc.Phase 3

See all EUCRISA clinical trials

Pharmacology for EUCRISA
Paragraph IV (Patent) Challenges for EUCRISA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
EUCRISA Topical Ointment crisaborole 2% 207695 5 2021-06-14

US Patents and Regulatory Information for EUCRISA

EUCRISA is protected by four US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of EUCRISA is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting EUCRISA

Boron-containing small molecules
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Boron-containing small molecules as anti-inflammatory agents
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Boron-containing small molecules as anti-inflammatory agents
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Boron-containing small molecules as anti-inflammatory agents
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

FDA Regulatory Exclusivity protecting EUCRISA

ADDITION OF A ONCE DAILY DOSING REGIMEN
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Anacor Pharms Inc EUCRISA crisaborole OINTMENT;TOPICAL 207695-001 Dec 14, 2016 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Anacor Pharms Inc EUCRISA crisaborole OINTMENT;TOPICAL 207695-001 Dec 14, 2016 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Anacor Pharms Inc EUCRISA crisaborole OINTMENT;TOPICAL 207695-001 Dec 14, 2016 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Anacor Pharms Inc EUCRISA crisaborole OINTMENT;TOPICAL 207695-001 Dec 14, 2016 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Anacor Pharms Inc EUCRISA crisaborole OINTMENT;TOPICAL 207695-001 Dec 14, 2016 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for EUCRISA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Pfizer Europe MA EEIG  Staquis crisaborole EMEA/H/C/004863
Staquis is indicated for treatment of mild to moderate atopic dermatitis in adults and paediatric patients from 2 years of age with ≤ 40% body surface area (BSA) affected.
Withdrawn no no no 2020-03-27
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for EUCRISA

When does loss-of-exclusivity occur for EUCRISA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 06214247
Estimated Expiration: ⤷  Try a Trial

Patent: 06333527
Estimated Expiration: ⤷  Try a Trial

Patent: 10203096
Estimated Expiration: ⤷  Try a Trial

Patent: 11200994
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 0608431
Estimated Expiration: ⤷  Try a Trial

Patent: 0621279
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 97982
Estimated Expiration: ⤷  Try a Trial

Patent: 35680
Estimated Expiration: ⤷  Try a Trial

China

Patent: 1160124
Estimated Expiration: ⤷  Try a Trial

Patent: 1505603
Estimated Expiration: ⤷  Try a Trial

Patent: 1914109
Estimated Expiration: ⤷  Try a Trial

Patent: 2532180
Estimated Expiration: ⤷  Try a Trial

Patent: 5949230
Estimated Expiration: ⤷  Try a Trial

Patent: 6008571
Estimated Expiration: ⤷  Try a Trial

Patent: 6008583
Estimated Expiration: ⤷  Try a Trial

Cyprus

Patent: 16454
Estimated Expiration: ⤷  Try a Trial

Patent: 20695
Estimated Expiration: ⤷  Try a Trial

Patent: 24503
Estimated Expiration: ⤷  Try a Trial

Patent: 20027
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 43304
Estimated Expiration: ⤷  Try a Trial

Patent: 87796
Estimated Expiration: ⤷  Try a Trial

Patent: 24932
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 53251
Estimated Expiration: ⤷  Try a Trial

Patent: 76536
Estimated Expiration: ⤷  Try a Trial

Patent: 43304
Estimated Expiration: ⤷  Try a Trial

Patent: 87796
Estimated Expiration: ⤷  Try a Trial

Patent: 24932
Estimated Expiration: ⤷  Try a Trial

France

Patent: C1024
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 09735
Estimated Expiration: ⤷  Try a Trial

Patent: 60139
Estimated Expiration: ⤷  Try a Trial

Patent: 21956
Estimated Expiration: ⤷  Try a Trial

Patent: 28917
Estimated Expiration: ⤷  Try a Trial

Hungary

Patent: 26021
Estimated Expiration: ⤷  Try a Trial

Patent: 40060
Estimated Expiration: ⤷  Try a Trial

Patent: 54365
Estimated Expiration: ⤷  Try a Trial

Patent: 000019
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 5080
Estimated Expiration: ⤷  Try a Trial

Patent: 2402
Estimated Expiration: ⤷  Try a Trial

Patent: 7156
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 38912
Estimated Expiration: ⤷  Try a Trial

Patent: 46876
Estimated Expiration: ⤷  Try a Trial

Patent: 09140
Estimated Expiration: ⤷  Try a Trial

Patent: 08535781
Estimated Expiration: ⤷  Try a Trial

Patent: 09526751
Estimated Expiration: ⤷  Try a Trial

Patent: 10248265
Estimated Expiration: ⤷  Try a Trial

Patent: 13018778
Estimated Expiration: ⤷  Try a Trial

Patent: 14132031
Estimated Expiration: ⤷  Try a Trial

Patent: 15117243
Estimated Expiration: ⤷  Try a Trial

Patent: 16020374
Estimated Expiration: ⤷  Try a Trial

Patent: 16199561
Estimated Expiration: ⤷  Try a Trial

Patent: 17105826
Estimated Expiration: ⤷  Try a Trial

Lithuania

Patent: 343304
Estimated Expiration: ⤷  Try a Trial

Patent: 2020524
Estimated Expiration: ⤷  Try a Trial

Luxembourg

Patent: 0157
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 5993
Estimated Expiration: ⤷  Try a Trial

Patent: 9262
Estimated Expiration: ⤷  Try a Trial

Netherlands

Patent: 1049
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 0448
Estimated Expiration: ⤷  Try a Trial

Patent: 8297
Estimated Expiration: ⤷  Try a Trial

Patent: 8441
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 53251
Estimated Expiration: ⤷  Try a Trial

Patent: 43304
Estimated Expiration: ⤷  Try a Trial

Patent: 87796
Estimated Expiration: ⤷  Try a Trial

Patent: 24932
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 53251
Estimated Expiration: ⤷  Try a Trial

Patent: 43304
Estimated Expiration: ⤷  Try a Trial

Patent: 87796
Estimated Expiration: ⤷  Try a Trial

Patent: 24932
Estimated Expiration: ⤷  Try a Trial

Russian Federation

Patent: 14906
Estimated Expiration: ⤷  Try a Trial

Patent: 06947
Estimated Expiration: ⤷  Try a Trial

Patent: 07134429
Estimated Expiration: ⤷  Try a Trial

Patent: 08131324
Estimated Expiration: ⤷  Try a Trial

Patent: 10133524
Estimated Expiration: ⤷  Try a Trial

Patent: 16145916
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 43304
Estimated Expiration: ⤷  Try a Trial

Patent: 87796
Estimated Expiration: ⤷  Try a Trial

Patent: 24932
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 0707408
Estimated Expiration: ⤷  Try a Trial

Patent: 0905950
Estimated Expiration: ⤷  Try a Trial

Patent: 1005380
Estimated Expiration: ⤷  Try a Trial

Patent: 1506944
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 1337045
Estimated Expiration: ⤷  Try a Trial

Patent: 1337068
Estimated Expiration: ⤷  Try a Trial

Patent: 1426220
Estimated Expiration: ⤷  Try a Trial

Patent: 1456815
Estimated Expiration: ⤷  Try a Trial

Patent: 070112390
Estimated Expiration: ⤷  Try a Trial

Patent: 080110984
Estimated Expiration: ⤷  Try a Trial

Patent: 100105869
Estimated Expiration: ⤷  Try a Trial

Patent: 130095330
Estimated Expiration: ⤷  Try a Trial

Patent: 130100019
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 14095
Estimated Expiration: ⤷  Try a Trial

Patent: 40966
Estimated Expiration: ⤷  Try a Trial

Patent: 86981
Estimated Expiration: ⤷  Try a Trial

Patent: 72962
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EUCRISA around the world.

Country Patent Number Title Estimated Expiration
Japan 6266708 ⤷  Try a Trial
Hungary E026021 ⤷  Try a Trial
Poland 1988779 ⤷  Try a Trial
Hungary E025048 ⤷  Try a Trial
Canada 2635680 PETITES MOLECULES CONTENANT DU BORE (BORON-CONTAINING SMALL MOLECULES) ⤷  Try a Trial
Hong Kong 1221956 用於治療感染的鹵代類苯酞化硼 (HALOGEN-SUBSTITUTED BORONOPHTHALIDES FOR THE TREATMENT OF INFECTIONS) ⤷  Try a Trial
China 102532180 Boron-containing small molecules ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for EUCRISA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2343304 SPC/GB20/025 United Kingdom ⤷  Try a Trial PRODUCT NAME: CRISABOROLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/19/1421 20200401; UK PLGB 00057-1691 20200401
2343304 C202030031 Spain ⤷  Try a Trial PRODUCT NAME: CRISABOROL, OPCIONALMENTE EN FORMA DE UNA SAL FARMACEUTICAMENTE ACEPTABLE; NATIONAL AUTHORISATION NUMBER: EU/1/19/1421; DATE OF AUTHORISATION: 20200327; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1421; DATE OF FIRST AUTHORISATION IN EEA: 20200327
2343304 20C1024 France ⤷  Try a Trial PRODUCT NAME: CRISABOROLE, OPTIONNELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/19/1421 20200401
2343304 PA2020524 Lithuania ⤷  Try a Trial PRODUCT NAME: KRISABOROLAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS FORMOJE; REGISTRATION NO/DATE: EU/1/19/1421 20200327
2343304 C 2020 030 Romania ⤷  Try a Trial PRODUCT NAME: CRISABOROL SI SARURILE SALE FARMACEUTIC ACCEPTABILE FARMACEUTIC; NATIONAL AUTHORISATION NUMBER: EU/1/19/1421; DATE OF NATIONAL AUTHORISATION: 20200327; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1421; DATE OF FIRST AUTHORISATION IN EEA: 20200327
2343304 2090017-1 Sweden ⤷  Try a Trial PRODUCT NAME: CRISABOROLE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REG. NO/DATE: EU/1/19/1421 20200401
2343304 PA2020524,C2343304 Lithuania ⤷  Try a Trial PRODUCT NAME: KRISABOROLAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS FORMOJE; REGISTRATION NO/DATE: EU/1/19/1421 20200327
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.